Peptide & GLP-1 Regulatory Trackers

Fast-moving facts — FDA approvals, compounding legality, and 2026 availability — distilled into dated, at-a-glance status pages. Each tracker is re-verified by the PeptidesDB Librarian and stamped with the date it was last checked.

GLP-1 & Weight Loss

Approval status and clinical progress for the GLP-1 class.

Retatrutide FDA Approval Tracker

Not approved — Phase 3

Tracking retatrutide — Eli Lilly's investigational triple GLP-1/GIP/glucagon receptor agonist — on its path to FDA approval. As of mid-2026 it remains in Phase 3 development and is not approved for any use.

Verified 2 hours ago

Regulatory & Legal

Compounding legality and the shifting rules around peptide access.

Compounded GLP-1 Legal Status

Restricted

The legality of compounded semaglutide and tirzepatide has tightened sharply since both drugs came off the FDA shortage list. This tracks what is — and isn't — permitted now.

Verified 1 hour ago

Availability

How and where patients can actually get these drugs right now.

GLP-1 Availability & Access (2026)

Expanding

How patients actually access GLP-1 drugs in 2026 — from the new oral semaglutide pill to direct-to-patient cash-pay programs — as telehealth compounding routes narrow.

Verified 18 minutes ago